OpenAI strikes again! Acquire biomedical AI startups and let Agent help pharmaceutical companies manage research and development

Zhixi Compiled | Sun Xiaowen Editor | Cheng Qian Zhixi reported on October 21 that early this morning, OpenAI announced that it had acquired Orchestra Bio, an American AI drug development collaboration platform, and integrated its team and technology into the life sciences business Rosalind. Founded in 2022, Orchestra mainly provides R&D management software for biotechnology companies and pharmaceutical companies, helping teams formulate R&D plans, manage budgets, and track project progress. Its founding team held early management positions at Benchling, a biological R&D software company. OpenAI hopes to build an intelligent agent that can coordinate drug development and help scientific research teams transform research findings into subsequent experiments, decisions and actions. As of press time, the parties have not disclosed the transaction amount. ▲OpenAI official website announcement 1. Orchestra uses AI to coordinate drug research and development and will be integrated with the OpenAI scientific research model. As of August 2025, Orchestra has received US$20 million in financing from investors including a16z, 8VC, Insight Partners, etc. Among them, 8VC is the leading investor in its Series A financing. In November of the same year, Orchestra reached a cooperation with MBC BioLabs, a biotechnology entrepreneurial community, to promote R&D management software to start-ups in the community. Orchestra said its customers include neurodegenerative diseases, cancer, metabolic diseases and biomanufacturing. OpenAI stated in the acquisition announcement that in the United States, it takes an average of about 10 to 15 years for a new drug to be approved from target discovery to approval. The R&D team not only has to solve scientific problems, but also coordinate internal departments and external partners. Information dispersion and interdependence of links increase the difficulty of management. For example, a batch of drug production failures may lead to delays in clinical trials. Orchestra's agent can sort out the affected tasks and schedules, summarize relevant information, and compare response options for scientists and project leaders to make decisions. Specifically, Orchestra will be integrated into R